Blue Bees Therapeutics is a biotechnology company founded in March 2022, dedicated to the development of first-in-class immunotherapies for the treatment of cancers, based on a breakthrough technology discovered by the team led by Dr Michel Léonetti, within the Department of Pharmacology and Immunoanalysis from CEA Paris-Saclay. This technology allows to generate antibodies stimulating the anti-tumor immune response via a double cell receptor targeting coupled with heparan sulphate proteoglycans (HSPG)." title="" class="btn" data-container="body" data-html="true" data-id="227550" data-placement="top" data-toggle="popover" data-trigger="focus" style="color:#0077b5" tabindex="0" data-original-title="Blue Bees Therapeutics"> 403
Activities
Technologies
Entity types
Location
21 Rue Jean Rostand, 91400 Orsay, France
Orsay
France
Employees
Scale: 2-10
Estimated: 9
Engaged corporates
7Added in Motherbase
1 year, 1 month agoBlue Bees Therapeutics develops immunomodulatory proteins with therapeutic potential to fight cancer
Blue Bees Therapeutics is a biotechnology company founded in March 2022, dedicated to the development of first-in-class immunotherapies for the treatment of cancers, based on a breakthrough technology discovered by the team led by Dr Michel Léonetti, within the Department of Pharmacology and Immunoanalysis from CEA Paris-Saclay.
This technology allows to generate antibodies stimulating the anti-tumor immune response via a double cell receptor targeting coupled with heparan sulphate proteoglycans (HSPG).
Immunothérapie, Immuno-oncologie, pharma, Biotech, Immunologie, Oncologie, Cancer, Médicament, and Drug
Blue Bees Therapeutics develops immunomodulatory proteins (antibodies) with therapeutic potential to fight cancer
Blue Bees Therapeutics is a biotechnology company, founded in March 2022, dedicated to the development of first-in-class immunotherapies for the treatment of cancers, based on a breakthrough technology discovered by the team led by Dr Michel Léonetti, within the Department of Pharmacology and Immunoanalysis from CEA Paris-Saclay.
This technology allows to generate antibodies stimulating the anti-tumor immune response via a double cell receptor targeting coupled with heparan sulphate proteoglycans (HSPG).
Blue Bees Therapeutics develops immunomodulatory proteins with therapeutic potential to fight cancer
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
![]() France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 20 Jun 2024 | | |
![]() CEA Research | CEA Research | Other 21 May 2024 | | |
![]() | Réseau SATT | Other 30 Apr 2024 | | |
![]() CNRS Research, Research Services | CNRS Research, Research Services | Other 30 Apr 2024 | | |
![]() Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 30 Apr 2024 | | |
![]() Genopole Biotechnology, Biotechnology Research | Genopole Biotechnology, Biotechnology Research | Other 23 Jan 2023 | | |
![]() SATT Paris-Saclay Research, Startup accelerator & VC, Research Services | SATT Paris-Saclay Research, Startup accelerator & VC, Research Services | Other 30 Apr 2024 | |